Cover Image

New treatment options for lupus – a focus on belimumab

Laurent Chiche1,2, Noémie Jourde3, Guillemette Thomas1, Nathalie Bardin2, Charleric Bornet4, Albert Darque4, Julien Mancini51Department of Internal Medicine, Centre de Compétence Maladies Auto-immunes Systémiques PACA Ouest, 2Laboratory of Immunology, 3Department of...

Full description

Saved in:

Bibliographic Details
Main Authors:	Chiche L (Author), Jourde N (Author), Thomas G (Author), Bardin N (Author), Bornet C (Author), Darque A (Author), Mancini J (Author)
Format:	Book
Published:	Dove Medical Press, 2012-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Belimumab for systemic lupus erythematosus - Focus on lupus nephritis
by: Marlene Plüß, et al.
Published: (2022)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
by: Guzman M, et al.
Published: (2020)

Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus
by: A. G. Tolkushin, et al.
Published: (2018)

Belimumab in systemic lupus erythematosus
by: Ankita Srivastava
Published: (2016)

FDA approves belimumab for treatment of children with lupus nephritis
by: article Editorial
Published: (2022)

Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain
by: Cevey M, et al.
Published: (2019)

Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
by: Ian N Bruce, et al.
Published: (2022)

Cost-effectiveness analysis of Belimumab in patients with systemic lupus erythematosus in Spain
by: Silvia Díaz-Cerezo, et al.
Published: (2015)

Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
by: Nick Ballew, et al.
Published: (2022)

Indeterminate Colitis – Update on Treatment Options
by: Venkateswaran N, et al.
Published: (2021)

Letter in reply: Crusted scabies mimicking a lupus flare after rituximab and belimumab
by: Grigoriy Androsov, BS, et al.
Published: (2021)

Serum IFN-γ Predicts the Therapeutic Effect of Belimumab in Refractory Lupus Nephritis Patients
by: Liu S, et al.
Published: (2024)

Novel treatment of systemic lupus erythematosus: belimumab is now available for Russian patients over 5 years old
by: article editorial
Published: (2020)

Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in China
by: Meng Tan, et al.
Published: (2023)

Population model‐based analysis of the memory B‐cell response following belimumab therapy in the treatment of systemic lupus erythematosus
by: Richard Dimelow, et al.
Published: (2023)

Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents
by: Lenert A, et al.
Published: (2015)

Evaluation of intra‐ and inter‐individual variations in plasma belimumab concentrations in adult patients with systemic lupus erythematosus
by: Chisato Yoshijima, et al.
Published: (2024)

Belimumab in a Patient with Systemic Lupus Erythematosus with Juvenile Onset and Steroid-induced Diabetes: Clinical Case
by: Maria I. Kaleda, et al.
Published: (2023)

Gynecomastia – evaluation and current treatment options
by: Johnson RE, et al.
Published: (2011)

The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients
by: Jing Wang, et al.
Published: (2023)

Usefulness of Belimumab in Adult Patients With Systemic Lupus Erythematosus Evaluated Using Single Indexes: A Meta-Analysis and Systematic Review
by: Chisato Yoshijima, BSPharm, et al.
Published: (2024)

Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab
by: Francesca Regola, et al.
Published: (2019)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
by: Clemens Warnke, et al.
Published: (2010)

New treatments for genotype 1 chronic hepatitis C – focus on simeprevir
by: Kanda T, et al.
Published: (2014)

Lipofilling: A New Therapeutic Option for the Treatment of Lupus Panniculitis-Induced Atrophy
by: Laura Polivka, et al.
Published: (2016)

Effectiveness and safety of belimumab in Chinese adult lupus nephritis patients: a 24-week retrospective single-center real-world study
by: Pei-pei Jiang, et al.
Published: (2024)

Targeting metastatic colorectal cancer – present and emerging treatment options
by: Ciombor KK, et al.
Published: (2014)

Bowen’s disease – a review of newer treatment options
by: Thorsten Neubert, et al.
Published: (2008)

New developments in the treatment of hypoactive sexual desire disorder – a focus on Flibanserin
by: Jayne CJ, et al.
Published: (2017)

Combating HIV resistance – focus on darunavir
by: Cécile L Tremblay
Published: (2008)

Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumab
by: Nakashima Y, et al.
Published: (2014)

Emerging treatments in the management of schizophrenia – focus on sertindole
by: Maria Rosaria A Muscatello, et al.
Published: (2010)

Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
by: AlDallal SM
Published: (2017)

Understanding lupus nephritis: diagnosis, management, and treatment options
by: Mok CC
Published: (2012)

Role of biologics in severe eosinophilic asthma – focus on reslizumab
by: Pelaia G, et al.
Published: (2016)

Focus on Antibiotics – New Challenges and Steps Forward in Discovery and Development
Published: (2023)

New and emerging contraceptive options: a focus on transdermal contraception
by: Böttcher B, et al.
Published: (2014)

Retargeting the management of hypercholesterolemia – focus on evolocumab
by: Colletti A, et al.
Published: (2016)

Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab
by: Naveed Wagle, et al.
Published: (2010)

Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine
by: Uml, et al.
Published: (2012)